Correction: Highly potent and selective phosphatidylinositol 4-kinase IIIβ inhibitors as broad-spectrum anti-rhinoviral agents

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics

MedChemComm Pub Date : 2024-06-12 DOI:10.1039/D4MD90022G

Avinash G. Vishakantegowda, Dasom Hwang, Prashant Chakrasali, Eunhye Jung, Joo-Youn Lee, Jin Soo Shin and Young-Sik Jung

引用次数: 0

Abstract

Correction for ‘Highly potent and selective phosphatidylinositol 4-kinase IIIβ inhibitors as broad-spectrum anti-rhinoviral agents’ by Avinash G. Vishakantegowda et al., RSC Med. Chem., 2024, 15, 704–719, https://doi.org/10.1039/D3MD00630A.

查看原文本刊更多论文

更正：作为广谱抗鼻病毒药物的高效力和选择性磷脂酰肌醇 4- 激酶 IIIβ 抑制剂

对 Avinash G. Vishakantegowda 等人发表的 "作为广谱抗鼻病毒药物的高效力和选择性磷脂酰肌醇 4- 激酶 IIIβ 抑制剂 "的更正。Vishakantegowda 等人，RSC Med.Chem.，2024，15，704-719，https://doi.org/10.1039/D3MD00630A。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL

CiteScore

4.70

自引率

0.00%

发文量

审稿时长

2.2 months

期刊介绍： Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.